Creo Medical Group PLC
LSE:CREO
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
16.125
48.1
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CREO stock under the Base Case scenario is 25.93 GBX. Compared to the current market price of 16.625 GBX, Creo Medical Group PLC is Undervalued by 36%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Creo Medical Group PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CREO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Creo Medical Group PLC
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Creo Medical Group PLC
Balance Sheet Decomposition
Creo Medical Group PLC
Current Assets | 32.1m |
Cash & Short-Term Investments | 9.8m |
Receivables | 13.8m |
Other Current Assets | 8.5m |
Non-Current Assets | 37.2m |
Long-Term Investments | 2.1m |
PP&E | 8.5m |
Intangibles | 25.2m |
Other Non-Current Assets | 1.4m |
Current Liabilities | 9.9m |
Accounts Payable | 5.4m |
Other Current Liabilities | 4.5m |
Non-Current Liabilities | 12m |
Long-Term Debt | 10.7m |
Other Non-Current Liabilities | 1.3m |
Earnings Waterfall
Creo Medical Group PLC
Revenue
|
30.3m
GBP
|
Cost of Revenue
|
-15.3m
GBP
|
Gross Profit
|
15m
GBP
|
Operating Expenses
|
-40.1m
GBP
|
Operating Income
|
-25.1m
GBP
|
Other Expenses
|
2.7m
GBP
|
Net Income
|
-22.4m
GBP
|
Free Cash Flow Analysis
Creo Medical Group PLC
GBP | |
Free Cash Flow | GBP |
CREO Profitability Score
Profitability Due Diligence
Creo Medical Group PLC's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Creo Medical Group PLC's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
CREO Solvency Score
Solvency Due Diligence
Creo Medical Group PLC's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Creo Medical Group PLC's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CREO Price Targets Summary
Creo Medical Group PLC
According to Wall Street analysts, the average 1-year price target for CREO is 58.65 GBX with a low forecast of 45.45 GBX and a high forecast of 73.5 GBX.
Dividends
Current shareholder yield for CREO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.
Contact
IPO
Employees
Officers
The intrinsic value of one CREO stock under the Base Case scenario is 25.93 GBX.
Compared to the current market price of 16.625 GBX, Creo Medical Group PLC is Undervalued by 36%.